A nanoparticulate drug-delivery system for glaucocalyxin A: formulation, characterization, increased in vitro, and vivo antitumor activity

References

• Amit S, Ben-Neriah Y. (2003). NF-kappaB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol 13:15–28
   PubMed Web of Science ®Google Scholar
• Arai T, Koyama Y, Suenaga T, et al. (1963). Antitumor activity of the components of Isodon trichocarpus and related plants. J Antibiot 16:132–8
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–59
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–51
   PubMed Web of Science ®Google Scholar
• Cao LY, Yan JC, Wang YS, et al. (2008). Preparation and physico-chemical property of glaucocalyxin A solid lipid nanoparticles. China Pharmacy 19:666–8
   Google Scholar
• Chen ZJ, Li YS, Zhou JY, et al. (2006). Effect of glaucocalyxin A on level of Th1/Th2 type cytokines in mice. Zhongguo Zhong Yao Za Zhi 31:1257–60
   PubMedGoogle Scholar
• Dai W, Zhang D, Duan C, et al. (2010). Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul 27:234–41
   PubMed Web of Science ®Google Scholar
• Des Rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1–27
   PubMed Web of Science ®Google Scholar
• Elzoghby AO, Samy WM, Elgindy NA. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–82
   PubMed Web of Science ®Google Scholar
• Hintz RJ, Johnson KC. (1989). The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 51:9–17
   Web of Science ®Google Scholar
• Kratz F. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83
   PubMed Web of Science ®Google Scholar
• Li M, Jiang XG, Gu ZL, et al. (2013). Glaucocalyxin A activates fasl and induces apoptosis through activation of the JNK pathway in human breast cancer cells. Asian Pac J Cancer Prev 14:5805–10
   PubMed Web of Science ®Google Scholar
• Lou H, Gao L, Wei X, et al. (2011). Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 87:319–25
   PubMed Web of Science ®Google Scholar
• Lou HY, Zhang XM, Gao L, et al. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 379:181–6
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Taoufik E, Haralambous S, et al. (2009). In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 71:190–5
   PubMed Web of Science ®Google Scholar
• Morita T, Horikiri Y, Suzuki T, et al. (2001). Preparation of gelatin microparticles by co-lyophilization with poly (ethylene glycol): characterization and application to entrapment into biodegradable microspheres. Int J Pharm 219:127–37
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–19
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:827–40
   PubMed Web of Science ®Google Scholar
• Shang XJ, Ma SY, Wu J, et al. (2011). Preparation of glaucocalyxin A-hydroxypropy-β-cyclodextrin inclusion complex. Chin J New Drug 20:1243–6
   Google Scholar
• Sun HD, Huang SX, Han QB. (2006). Diterpenoids from Isodon species and their biological activities. Nat Prod Rep 23:673–98
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Hu W, et al. (2010). Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 6:371–81
   PubMed Web of Science ®Google Scholar
• Wei L, Xiao RT, Wen XY, et al. (2013). Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway. PloS One 12:1–15
   Google Scholar
• Xiang ZB, Xu YX, Shen Y, et al. (2008). Two new diterpenoids from Rabdosia japonica var. Glaucocalyx. Zhongguo Hua Xue Kuai Bao 19:852–4
   Web of Science ®Google Scholar
• Xu FM, Hu HP, Wang ZQ. (1996). Studies on diterpenoid constituents in Rabdosia japonica (Burm.f.) Hara. Zhongguo Zhong Yao Za Zhi 21:678–9
   PubMedGoogle Scholar
• Yang LJ, Zhang J, Shi JW, et al. (2012). Preparation and properties of glaucocalyxin A-loaded self-assemble nanomicelles. Yiyao Dao Bao 31:775–8
   Google Scholar
• Ye Q, Zhang Z, Jia H, et al. (2002). Formation of monodisperse polyacrylamide particles by radiation-induced dispersion polymerization: particle size and size distribution. J Colloid Interface Sci 253:279–84
   PubMed Web of Science ®Google Scholar
• Zhang B, Long K. (1993). Effects of glaucocalyxin A on aggregation and cAMP levels of rabbit platelets in vitro. Zhongguo Yao Li Xue Bao 14:347–50
   PubMed Web of Science ®Google Scholar
• Zhang DR, Ren TC. (2003). The advance in pharmaceutical research on oridonin. Zhongguo Yao Xue Za Zhi 11:817–20
   Google Scholar
• Zhang DY, Li ZY, Shi LY, et al. (2008). Advances in research on cytotoxinic activity of ent-Kaurane diterpenoids. Chin J Org Chem 11:1911–17
   Google Scholar
• Zhang JX, Han QB, Zhao AH, et al. (2003). Diterpenoids from Isodon japonica. Fitoterapia 74:435–8
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang M, Wang Q, et al. (2007). 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release 119:153–62
   PubMed Web of Science ®Google Scholar
• Zhao YX, Hua HY, Chang M, et al. (2010). Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm 392:64–71
   PubMed Web of Science ®Google Scholar